Catalyst Event
Novo Nordisk A/S (NVO) · Other
From KEDI Global Obesity Care Industry Top 2+ Index (OBCI)
3/25/2026, 12:00:00 AM
Announced positive topline results from a Phase 2 trial in China for UBT251, a 'triple G' agonist, showing superior blood sugar and weight reduction compared to semaglutide in patients with type 2 diabetes.
Korean Translation
제2형 당뇨병 환자를 대상으로 한 '트리플 G' 작용제 UBT251의 중국 2상 임상시험에서 세마글루타이드 대비 우수한 혈당 및 체중 감소 효과를 보인 긍정적인 탑라인 결과를 발표함.
Related Recent Events
DICK'S Sporting Goods Inc (DKS) · Earnings Release
First quarter 2026 earnings release is scheduled.
5/27/2026, 12:00:00 AM
Planet Fitness Inc (PLNT) · Earnings Release
Q1 2026 earnings release on 2026-05-07 is scheduled. A typical 1-2% price movement is estimated.
5/7/2026, 12:00:00 AM
Novo Nordisk A/S (NVO) · Earnings Release
First quarter 2026 financial results announcement scheduled.
5/6/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Earnings Release
First quarter 2026 earnings release and conference call, which is estimated to have a >=10% price impact, is scheduled.
4/30/2026, 12:00:00 AM
Merck and Co Inc (MRK) · Earnings Release
Merck will report Q1 2026 earnings and host its earnings call on 2026-04-30, which is likely to be material given the strong market sensitivity to its recent guidance outlook, scheduled.
4/30/2026, 12:00:00 AM
Novartis AG (NVS) · Earnings Release
First quarter 2026 earnings results, with low impact expected from the date announcement, scheduled
4/28/2026, 12:00:00 AM